Accelerated reconstitution of platelets and erythrocytes after syngeneic transplantation of bone marrow cells derived from thrombopoietin pretreated donor mice.

Thrombopoietin expands hematopoietic stem cells after transplantation. J Clin Invest (2002) 1.63

New thrombopoietic growth factors. Blood (2007) 1.39

Thrombopoietin rescues in vitro erythroid colony formation from mouse embryos lacking the erythropoietin receptor. Proc Natl Acad Sci U S A (1996) 1.39

The thrombopoietin receptor, c-Mpl, is a selective surface marker for human hematopoietic stem cells. J Transl Med (2006) 0.88

Are there more tricks in the bag for treating thrombocytopenia? J Clin Invest (2010) 0.84

Exogenous endothelial cells as accelerators of hematopoietic reconstitution. J Transl Med (2012) 0.79

A syndrome of multiorgan hyperplasia with features of gigantism, tumorigenesis, and female sterility in p27(Kip1)-deficient mice. Cell (1996) 8.41

TACI and BCMA are receptors for a TNF homologue implicated in B-cell autoimmune disease. Nature (2000) 6.54

Transgenetic studies implicate interactions between homologous PrP isoforms in scrapie prion replication. Cell (1990) 6.17

Interleukin 21 and its receptor are involved in NK cell expansion and regulation of lymphocyte function. Nature (2000) 5.86

Transgenic mice expressing hamster prion protein produce species-specific scrapie infectivity and amyloid plaques. Cell (1989) 4.73

Autologous or allogeneic bone marrow transplantation compared with intensive chemotherapy in acute myelogenous leukemia. European Organization for Research and Treatment of Cancer (EORTC) and the Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto (GIMEMA) Leukemia Cooperative Groups. N Engl J Med (1995) 4.19

Spontaneous neurodegeneration in transgenic mice with mutant prion protein. Science (1990) 4.19

Ablation of the prion protein (PrP) gene in mice prevents scrapie and facilitates production of anti-PrP antibodies. Proc Natl Acad Sci U S A (1993) 3.56

Propagation of prions with artificial properties in transgenic mice expressing chimeric PrP genes. Cell (1993) 2.93

Specificity of leptin action on elevated blood glucose levels and hypothalamic neuropeptide Y gene expression in ob/ob mice. Diabetes (1996) 2.83

Transmission of Creutzfeldt-Jakob disease from humans to transgenic mice expressing chimeric human-mouse prion protein. Proc Natl Acad Sci U S A (1994) 2.70

Cutting edge: the common gamma-chain is an indispensable subunit of the IL-21 receptor complex. J Immunol (2001) 2.69

Degeneration of skeletal muscle, peripheral nerves, and the central nervous system in transgenic mice overexpressing wild-type prion proteins. Cell (1994) 2.68

Chimeric prion protein expression in cultured cells and transgenic mice. Protein Sci (1992) 2.67

Hypoxic induction of human vascular endothelial growth factor expression through c-Src activation. Nature (1995) 2.61

Differential expression of CXCR3 targeting chemokines CXCL10, CXCL9, and CXCL11 in different types of skin inflammation. J Pathol (2001) 2.57

Interleukin 20: discovery, receptor identification, and role in epidermal function. Cell (2001) 2.45

ALK expression in extranodal anaplastic large cell lymphoma favours systemic disease with (primary) nodal involvement and a good prognosis and occurs before dissemination. J Clin Pathol (2000) 2.43

Cloning and expression of murine thrombopoietin cDNA and stimulation of platelet production in vivo. Nature (1994) 2.41

Serial transmission in rodents of neurodegeneration from transgenic mice expressing mutant prion protein. Proc Natl Acad Sci U S A (1994) 2.37

Primary and secondary cutaneous CD30(+) lymphoproliferative disorders: a report from the Dutch Cutaneous Lymphoma Group on the long-term follow-up data of 219 patients and guidelines for diagnosis and treatment. Blood (2000) 2.25

The Polycomb group protein EZH2 is upregulated in proliferating, cultured human mantle cell lymphoma. Br J Haematol (2001) 2.21

Cytokines in chronic inflammatory arthritis. II. Granulocyte-macrophage colony-stimulating factor in rheumatoid synovial effusions. J Clin Invest (1989) 2.18

Melanocortin 1 receptor (MC1R) gene variants are associated with an increased risk for cutaneous melanoma which is largely independent of skin type and hair color. J Invest Dermatol (2001) 2.16

Cytokines in chronic inflammatory arthritis. VI. Analysis of the synovial cells involved in granulocyte-macrophage colony-stimulating factor production and gene expression in rheumatoid arthritis and its regulation by IL-1 and tumor necrosis factor-alpha. J Immunol (1991) 2.09

Tumor necrosis factor type alpha stimulates human endothelial cells to produce granulocyte/macrophage colony-stimulating factor. Proc Natl Acad Sci U S A (1986) 2.06

Response to interferon alfa-2b in a patient with systemic mastocytosis. N Engl J Med (1992) 1.95

The effect of thrombopoietin on the proliferation and differentiation of murine hematopoietic stem cells. Blood (1996) 1.91

Mice lacking tartrate-resistant acid phosphatase (Acp 5) have disrupted endochondral ossification and mild osteopetrosis. Development (1996) 1.88

Signal transduction through lipid second messengers. Curr Opin Cell Biol (1996) 1.84

A retinoic acid-responsive human zinc finger gene, MZF-1, preferentially expressed in myeloid cells. J Biol Chem (1991) 1.83

Production of a severe cystic fibrosis mutation in mice by gene targeting. Nat Genet (1993) 1.80

Primary cutaneous large B-cell lymphomas of the legs. A distinct type of cutaneous B-cell lymphoma with an intermediate prognosis. Dutch Cutaneous Lymphoma Working Group. Arch Dermatol (1996) 1.77

Thrombopoietin signal transduction in purified murine megakaryocytes. Blood (1997) 1.75

Cloning and primary structure of a human islet isoform of glutamic acid decarboxylase from chromosome 10. Proc Natl Acad Sci U S A (1991) 1.74

Long-term safety aspects of systemic therapy with fumaric acid esters in severe psoriasis. Br J Dermatol (2003) 1.72

Thrombopoietin (c-mpl ligand) acts synergistically with erythropoietin, stem cell factor, and interleukin-11 to enhance murine megakaryocyte colony growth and increases megakaryocyte ploidy in vitro. Blood (1995) 1.71

CD56+ hematological neoplasms presenting in the skin: a retrospective analysis of 23 new cases and 130 cases from the literature. Ann Oncol (2004) 1.63

Interleukin-8 induces rapid mobilization of hematopoietic stem cells with radioprotective capacity and long-term myelolymphoid repopulating ability. Blood (1995) 1.62

Captopril-associated agranulocytosis. Lancet (1980) 1.61

Dysregulated expression of neutrophil apoptosis in the systemic inflammatory response syndrome. Arch Surg (1997) 1.60

Activation of the c-myc oncogene in a precursor-B-cell blast crisis of follicular lymphoma, presenting as composite lymphoma. N Engl J Med (1988) 1.59

Cloning of human Bcl-2 homologue: inflammatory cytokines induce human A1 in cultured endothelial cells. Blood (1996) 1.57

Secretable human platelet-derived factor V originates from the plasma pool. Blood (1998) 1.57

In vivo production of interleukin-5, granulocyte-macrophage colony-stimulating factor, macrophages colony-stimulating factor, and interleukin-6 during intravenous administration of high-dose interleukin-2 in cancer patients. Blood (1991) 1.55

Molecular remission in PML/RAR alpha-positive acute promyelocytic leukemia by combined all-trans retinoic acid and idarubicin (AIDA) therapy. Gruppo Italiano-Malattie Ematologiche Maligne dell'Adulto and Associazione Italiana di Ematologia ed Oncologia Pediatrica Cooperative Groups. Blood (1997) 1.53

Amino acid sequence of human histidine-rich glycoprotein derived from the nucleotide sequence of its cDNA. Biochemistry (1986) 1.52

Primary extranodal and nodal non-Hodgkin's lymphoma. A survey of a population-based registry. Eur J Cancer Clin Oncol (1989) 1.51

Paradoxical shortening of scrapie incubation times by expression of prion protein transgenes derived from long incubation period mice. Neuron (1991) 1.51

The serpin proteinase inhibitor 9 is an endogenous inhibitor of interleukin 1beta-converting enzyme (caspase-1) activity in human vascular smooth muscle cells. J Exp Med (2000) 1.50

HLA-DR4 is associated with a diminished risk of the development of chronic myeloid leukemia (CML). Chronic Leukemia Working Party of the European Blood and Marrow Transplant Registry. Leukemia (2000) 1.49

Mechanisms of cytomegalovirus-mediated myelosuppression: perturbation of stromal cell function versus direct infection of myeloid cells. Proc Natl Acad Sci U S A (1990) 1.49

Prevention of interleukin-8-induced mobilization of hematopoietic progenitor cells in rhesus monkeys by inhibitory antibodies against the metalloproteinase gelatinase B (MMP-9). Proc Natl Acad Sci U S A (1999) 1.49

Intensive chemotherapy followed by allogeneic or autologous stem cell transplantation for patients with myelodysplastic syndromes (MDSs) and acute myeloid leukemia following MDS. Blood (2001) 1.48

Varicella zoster virus (VZV)-related progressive outer retinal necrosis (PORN) after allogeneic stem cell transplantation. Bone Marrow Transplant (2005) 1.48

Granulocyte-macrophage colony-stimulating factor associated with induction treatment of acute myelogenous leukemia: a randomized trial by the European Organization for Research and Treatment of Cancer Leukemia Cooperative Group. J Clin Oncol (1996) 1.47

Genomic cloning, characterization, and multilineage growth-promoting activity of human granulocyte-macrophage colony-stimulating factor. Proc Natl Acad Sci U S A (1986) 1.46

Characterization of a cDNA coding for human protein C. Proc Natl Acad Sci U S A (1984) 1.45

Thrombopoietin: platelets on demand? Ann Intern Med (1997) 1.42

Production of tumor necrosis factor-alpha by normal and malignant B lymphocytes in response to interferon-alpha, interferon-gamma and interleukin-4. Leukemia (1992) 1.42

Primary cutaneous CD8-positive epidermotropic cytotoxic T cell lymphomas. A distinct clinicopathological entity with an aggressive clinical behavior. Am J Pathol (1999) 1.42

Diagnostic value of T-cell receptor beta gene rearrangement analysis on peripheral blood lymphocytes of patients with erythroderma. J Invest Dermatol (1991) 1.42

Stage is a better prognostic indicator than morphologic subtype in primary noncutaneous T-cell lymphoma. Am J Clin Pathol (1990) 1.41

New concepts in the classification of cutaneous lymphomas. Arch Dermatol (1995) 1.41

Induction of CD11a/leukocyte function antigen-1 and CD54/intercellular adhesion molecule-1 on hairy cell leukemia cells is accompanied by enhanced susceptibility to T-cell but not lymphokine-activated killer-cell cytotoxicity. Blood (1992) 1.40

Tissue factor pathway inhibitor-2 is a novel inhibitor of matrix metalloproteinases with implications for atherosclerosis. J Clin Invest (2001) 1.40

Dissecting the thrombopoietin receptor: functional elements of the Mpl cytoplasmic domain. Proc Natl Acad Sci U S A (1997) 1.39

UTY gene codes for an HLA-B60-restricted human male-specific minor histocompatibility antigen involved in stem cell graft rejection: characterization of the critical polymorphic amino acid residues for T-cell recognition. Blood (2000) 1.38

Removing the cloud from industry-sponsored, multicentered clinical trials. Blood (2001) 1.38

Human IP-9: A keratinocyte-derived high affinity CXC-chemokine ligand for the IP-10/Mig receptor (CXCR3). J Invest Dermatol (1999) 1.37

The c-Mpl ligand (thrombopoietin) stimulates tyrosine phosphorylation of Jak2, Shc, and c-Mpl. J Biol Chem (1995) 1.36

Progress in allogenic bone marrow and peripheral blood stem cell transplantation for multiple myeloma: a comparison between transplants performed 1983--93 and 1994--8 at European Group for Blood and Marrow Transplantation centres. Br J Haematol (2001) 1.36

Thrombopoietin-induced activation of the mitogen-activated protein kinase (MAPK) pathway in normal megakaryocytes: role in endomitosis. Blood (1999) 1.34

Thrombopoietin, the ligand for the Mpl receptor, synergizes with steel factor and other early acting cytokines in supporting proliferation of primitive hematopoietic progenitors of mice. Blood (1996) 1.31

Interleukin 1 stimulates human endothelial cells to produce granulocyte-macrophage colony-stimulating factor and granulocyte colony-stimulating factor. J Immunol (1987) 1.30

Sports injuries at the 1985 Junior Olympics. An epidemiologic analysis. Am J Sports Med (1988) 1.29

Mycosis fungoides: disease evolution and prognosis of 309 Dutch patients. Arch Dermatol (2000) 1.29

Prognostic factors in primary cutaneous large B-cell lymphomas: a European multicenter study. J Clin Oncol (2001) 1.28

DFFRY codes for a new human male-specific minor transplantation antigen involved in bone marrow graft rejection. Blood (2000) 1.26

Alcohol consumption raises HDL cholesterol levels by increasing the transport rate of apolipoproteins A-I and A-II. Circulation (2000) 1.25

Thrombopoietin induces phosphoinositol 3-kinase activation through SHP2, Gab, and insulin receptor substrate proteins in BAF3 cells and primary murine megakaryocytes. J Biol Chem (2000) 1.23

Complete remission of accelerated phase chronic myeloid leukemia by treatment with leukemia-reactive cytotoxic T lymphocytes. Blood (1999) 1.23

Clonal hematopoiesis in patients with acquired aplastic anemia. Blood (1991) 1.22

Anthracycline-based chemotherapy as primary treatment for intravascular lymphoma. Ann Oncol (2004) 1.22

The thrombopoietin receptor c-MPL activates JAK2 and TYK2 tyrosine kinases. Exp Hematol (1995) 1.21

The stem cell mobilizing capacity of patients with acute myeloid leukemia in complete remission correlates with relapse risk: results of the EORTC-GIMEMA AML-10 trial. Leukemia (2003) 1.21

Granzyme B-expressing peripheral T-cell lymphomas: neoplastic equivalents of activated cytotoxic T cells with preference for mucosa-associated lymphoid tissue localization. Blood (1994) 1.20

Stromal cell-derived factor-1 (SDF-1) acts together with thrombopoietin to enhance the development of megakaryocytic progenitor cells (CFU-MK). Blood (2000) 1.19

Rejection of bone-marrow graft by recipient-derived cytotoxic T lymphocytes against minor histocompatibility antigens. Lancet (1990) 1.19

Thrombopoietin signal transduction requires functional JAK2, not TYK2. J Biol Chem (1999) 1.18

Antisense oligonucleotides from the stage-specific myeloid zinc finger gene MZF-1 inhibit granulopoiesis in vitro. J Exp Med (1991) 1.17

Studies on clonality by PCR analysis of the PGK-1 gene. Nucleic Acids Res (1991) 1.16

CAMPATH-1H monoclonal antibody in therapy for previously treated low-grade non-Hodgkin's lymphomas: a phase II multicenter study. European Study Group of CAMPATH-1H Treatment in Low-Grade Non-Hodgkin's Lymphoma. J Clin Oncol (1998) 1.15

Transplantation of peripheral blood stem cells as compared with bone marrow from HLA-identical siblings in adult patients with acute myeloid leukemia and acute lymphoblastic leukemia. J Clin Oncol (2002) 1.15

Primary gastrointestinal non-Hodgkin's lymphoma in a population-based registry. Br J Cancer (1989) 1.15

Factors influencing release of granulocyte-macrophage colony-stimulating activity from human mononuclear phagocytes. Eur J Haematol (1988) 1.15

Generation of leukemia-reactive cytotoxic T lymphocyte clones from the HLA-identical bone marrow donor of a patient with leukemia. J Exp Med (1992) 1.15